4-氯苯丙酸乙酯 | 7116-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯苯丙酸乙酯
• 中文别名: 对氯苯丙酸乙酯；3-(4-氯苯基)丙酸乙酯；3-(4-氯-苯基)-丙酸乙酯
• 英文名称: ethyl 3-(4-chlorophenyl)propanoate
• 英文别名: ethyl 3-(p-chlorophenyl)-propanoate；Ethyl p-chlorohydrocinnamate
• CAS: 7116-36-1
• 化学式: C₁₁H₁₃ClO₂
• 分子量: 212.676
• InChiKey: YNEYMDBBOTWIAL-UHFFFAOYSA-N

物化性质

• 沸点：
  158-159℃/15Torr

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  4-氯苯丙酸乙酯 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 硫酸 、 氯化铵 、 pyridinium chlorochromate 、 sodium nitrite 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 70.0h， 生成 rac-2-hydroxy-4-(4-chlorophenyl)butanoic acid
  参考文献：
  名称：

  乳酸菌对（杂）芳基-脂肪族α-羟基羧酸的生物催化外消旋化。通过氧化-还原序列进行

  摘要：

  一系列（杂）芳基-和（二）芳基-脂肪族α-羟基羧酸的生物催化外消旋化已通过使用乳杆菌属的整个静息细胞实现。基本上温和的（生理）反应条件确保抑制不需要的副反应，例如消除、分解或缩合。使用副干酪乳杆菌 DSM 20207 无细胞提取物的辅因子/抑制剂研究表明，添加氧化还原辅因子 (NAD+/NADH) 导致外消旋化率明显增加，而在存在硫代-NAD+ 的情况下观察到强烈的抑制作用，这表明外消旋化是通过氧化还原序列进行的，而不是“外消旋酶”的参与。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

  DOI：

  10.1002/ejoc.200600454
• 作为产物：
  描述：

  对氯肉桂酸 在 palladium on activated charcoal 氢气 、 氢气 作用下， 生成 4-氯苯丙酸乙酯
  参考文献：
  名称：

  Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17α-hydroxylase/17,20-lyase (P45017α)

  摘要：

  We report the preliminary results of the synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a number of phenyl alkyl imidazole-based compounds as inhibitors of the two components of 17 alpha-hydroxylase/17,20-lyase (P450(17 alpha)), that is, 17 alpha-hydroxylase (17 alpha-OHase) and 17,20-lyase (lyase). The results show that N-3-(4-bromophenyl) propyl imidazole (12) (IC50 = 2.95 mu M against 17 alpha-OHase and IC50 = 0.33 mu M against lyase) is the most potent compound within the current study, in comparison to ketoconazole (KTZ) (IC50 = 3.76 mu M against 17 alpha-OHase and IC50 = 1.66 mu M against lyase). Modelling of these compounds suggests that the length of the alkyl chain enhances the interaction between the inhibitor and the area of the active site corresponding to the C(3) area of the steroid backbone, thereby increasing potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.092

文献信息

• Selective hydrogenation of α,β-unsaturated carbonyl compounds on silica-supported copper nanoparticles
  作者：Jorge Mendes-Burak、Behnaz Ghaffari、Christophe Copéret

  DOI：10.1039/c8cc08457b

  日期：——

  Silica-supported copper nanoparticles prepared via surface organometallic chemistry are highly efficient for the selective hydrogenation of various α,β-unsaturated carbonyl compounds yielding the corresponding saturated esters, ketones, and aldehydes in the absence of additives. High conversions and selectivities (>99%) are obtained for most substrates upon hydrogenation at 100–150 °C and under 25

  通过表面有机金属化学方法制备的二氧化硅负载的铜纳米粒子对于各种α，β-不饱和羰基化合物的选择性加氢反应非常高效，可在没有添加剂的情况下产生相应的饱和酯，酮和醛。在100–150°C和25 bar H 2下氢化时，大多数底​​物均获得高转化率和选择性（> 99％）。
• Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them
  申请人：——

  公开号：US20040072871A1

  公开（公告）日：2004-04-15

  A compound of formula (I) selected from: 1 wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C 1 -C 6 )alkyl-, R a represents hydrogen, halogen, (C 1 -C 3 )alkyl, hydroxyl or (C 1 -C 3 )alkoxy, R b represents hydrogen, halogen or (C 1 -C 3 )alkyl, A represents phenyl, pyridyl, (C 5 -C 6 )cycloalkyl or (C 5 -C 6 )cycloalkenyl, R 1 and R 2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR 4 , —NR 4 R 5 , —S(O) n R 4 , —C(O)R 4 , —CO 2 R 4 , —O—C(O)R 4 , —C(O)NR 4 R 5 , —NR 5 —C(O)R 4 , —NR 5 —SO 2 R 4 , -T-CN, -T-OR 4 , -T-OCF 3 , -T- NR 4 R 5 , -T-S(O) n R 4 , -T-C(O)R 4 , -T-CO 2 R 4 , -T-O—C(O)R 4 , -T-C(O)NR 4 R 5 , -T-NR 4 —C(O)R 5 , -T-NR 4 —SO 2 R 5 , —R 6 and -T-R 6 in which n, T, R 4 , R 5 and R 6 are as defined in the description, R 3 represents an —R 7 or —U—R 11 group in which R 7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R 11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.

  公式（I）所选的化合物如下： 其中： X代表氧或硫， Y代表氧，-NH-或-N（C1-C6）烷基-， Ra代表氢，卤素，（C1-C3）烷基，羟基或（C1-C3）甲氧基， Rb代表氢，卤素或（C1-C3）烷基， A代表苯基，吡啶基，（C5-C6）环烷基或（C5-C6）环烯基， R1和R2分别代表从氢，卤素，氰基，硝基，卤代烷基，卤代甲氧基，烷基，烯基，炔基，-OR4，-NR4R5，-S（O）nR4，-C（O）R4，-CO2R4，-O—C（O）R4，-C（O）NR4R5，-NR5—C（O）R4，-NR5—SO2R4，-T-CN，-T-OR4，-T-OCF3，-T-NR4R5，-T-S（O）nR4，-T-C（O）R4，-T-CO2R4，-T-O—C（O）R4，-T-C（O）NR4R5，-T-NR4—C（O）R5，-T-NR4—SO2R5，-R6和-T-R6中选择的基团，其中n，T，R4，R5和R6如描述中所定义， R3代表-R7或-U-R11基团，其中R7代表氢，烷基，芳基，环烷基或杂环烷基，U代表线性或支链烷基链，R11如描述中所定义， 它们的光学异构体或它们与药学上可接受的酸或碱形成的加合盐，以及它们作为金属蛋白酶抑制剂，更具体地是金属蛋白酶-12的抑制剂的用途。
• Anodic benzylic C(sp³)–H amination: unified access to pyrrolidines and piperidines
  作者：Sebastian Herold、Daniel Bafaluy、Kilian Muñiz

  DOI：10.1039/c8gc01411f

  日期：——

  important heterocyclic motifs of pyrrolidines and piperidines within a uniform reaction protocol. The mechanism of this unprecedented C–H amination strategy involves anodic C–H activation to generate a benzylic cation, which is efficiently trapped by a nitrogen nucleophile. The applicability of the process is demonstrated for 40 examples comprising both 5- and 6-membered ring formations.

  开发了一种电化学脂肪族CH胺化策略，以在统一的反应方案中访问吡咯烷和哌啶的重要杂环基序。这种前所未有的C–H胺化策略的机制涉及阳极C–H活化以生成苄基阳离子，该阳离子被氮亲核试剂有效捕获。对于包含5元和6元环形成的40个实例证明了该方法的适用性。
• Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors
  作者：Valeria La Pietra、Stefania Sartini、Lorenzo Botta、Alessandro Antonelli、Silvia Martina Ferrari、Poupak Fallahi、Alessio Moriconi、Vito Coviello、Luca Quattrini、Yi-Yu Ke、Hsieh Hsing-Pang、Federico Da Settimo、Ettore Novellino、Concettina La Motta、Luciana Marinelli

  DOI：10.1016/j.ejmech.2018.02.080

  日期：2018.4

  within the protein active site (V804L and V804M). Pursuing a receptor-based virtual screening against the kinase domain of RET, we found that compound 5 is able to inhibit efficiently both wild type and V804L mutant RET. Compound 5 was able to significantly reduce proliferation of both commercially available TT cell lines and surgical thyroid tissues obtained from patients with MTC and displayed a suitable

  现在已知，RET（在转染过程中重新排列）激酶的“功能获得”突变是甲状腺髓样癌（MTC）发作时的特异性和关键致癌事件。尽管存在许多RET抑制剂并且能够抑制RET变体（其中突变位于酶活性位点之外），但是当突变位于蛋白活性位点（V804L和V804M）内时，大多数突变体无效。进行针对RET激酶域的基于受体的虚拟筛选，我们发现化合物5能够有效抑制野生型和V804L突变RET。化合物5 能够显着降低从MTC患者那里获得的市售TT细胞系和甲状腺手术组织的增殖，并显示出合适的类药物特性，因此成为临床上无反应的MTC的进一步开发的有希望的候选者。
• 2-IMIDAZOLINES
  申请人：Galley Guido

  公开号：US20090018180A1

  公开（公告）日：2009-01-15

  The present invention relates to compounds of formula I wherein X—Y, R 1 , and n are as defined herein and to their pharmaceutically active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X—Y、R1和n如本文所定义，并且涉及它们的药用活性盐。式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1，适用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。